Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.
about
Recent advances in T-cell engineering for use in immunotherapyStructure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Opportunities and challenges for TCR mimic antibodies in cancer therapyNovel immunotherapies for the treatment of melanoma.Acute myeloid leukemia targets for bispecific antibodies.Targeting neoantigens to augment antitumour immunity.Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumorsImproved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in miceTiming Is Everything: Combining Post-Transplantation Adoptive Cell Therapy and Tumor Vaccines.Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Redirecting T cells to hematological malignancies with bispecific antibodies.Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy.Engineering chimeric antigen receptor-T cells for cancer treatment.Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma.Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer TherapyBispecific antibodies in cancer immunotherapyImmune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic optionFrontiers and Opportunities: Highlights of the 2 Annual Conference of the Chinese Antibody Society
P2860
Q28080312-99F5393A-C049-4AE7-AEFA-58864E8E9935Q30382749-BE0AE2EF-AB54-4F9A-AEA9-25CB0D711285Q38700209-1696C742-EBF4-4FAB-82B8-52EB6D3AE822Q38719407-BDBE3188-9143-45B1-B2D1-A41DCCAACD88Q38739446-CC0DD3BB-647F-400B-804D-B204E566A80BQ38788557-0BA3FB66-768C-4026-B070-76E3B69E18D3Q38808823-E21C7599-4AF6-4EEF-A26A-9AD97D370E11Q38812269-59877AA7-38D5-4545-AC0A-60F86D7E4C9FQ38824190-7BF02666-107F-476C-8678-8F575C70EDF2Q39117761-41127EB2-06D7-40F5-BF17-044ACDD272EFQ39149196-4EAF17C6-9924-49AB-847D-C40C14B85840Q40973052-2B7C0416-FE05-46BF-8196-F5B3F71649ECQ40994161-79EB6CAC-2B8C-4F38-9D31-2AC2ECB52BF5Q41879726-9223314F-B775-431D-9A04-3E8214F38FAFQ47147990-0065C2A1-B9F9-460E-96D8-93DDCF7F0F25Q47570358-50A8FFCC-7878-4241-9F0E-D7FC9F6F794CQ47570404-300AC88F-30AC-4C64-BC01-3B5F42CFF4A8Q48339827-B31DF460-6813-4E41-A750-9D5CDE18DC3AQ49897464-D07CDB32-4FEA-4A7A-A768-AA8512568266Q49962991-34F1979B-4230-4614-B3A9-094305FCB79FQ50426810-8C100EDC-EAAC-4BA8-B660-6A28351D2F18Q52716114-4B6FB35D-BD36-414E-A30F-7DD5F27A544AQ56890857-8D6C953F-83B0-4C4B-BE89-C9D4683888D0Q56893015-518EACF4-268B-451E-BB9C-2D75FCF3857EQ57165694-B042CEDB-E2FB-499A-A7EF-8A62EDFC51ECQ58556647-7B9867BF-6665-48D9-A034-E1E3A44DCA99
P2860
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Therapeutic bispecific T-cell ...... intracellular oncoprotein WT1
@nl
Therapeutic bispecific T-cell ...... intracellular oncoprotein WT1.
@ast
Therapeutic bispecific T-cell ...... intracellular oncoprotein WT1.
@en
type
label
Therapeutic bispecific T-cell ...... intracellular oncoprotein WT1
@nl
Therapeutic bispecific T-cell ...... intracellular oncoprotein WT1.
@ast
Therapeutic bispecific T-cell ...... intracellular oncoprotein WT1.
@en
prefLabel
Therapeutic bispecific T-cell ...... intracellular oncoprotein WT1
@nl
Therapeutic bispecific T-cell ...... intracellular oncoprotein WT1.
@ast
Therapeutic bispecific T-cell ...... intracellular oncoprotein WT1.
@en
P2093
P2860
P921
P3181
P356
P1433
P1476
Therapeutic bispecific T-cell ...... intracellular oncoprotein WT1.
@en
P2093
David A Scheinberg
Dmitry Pankov
Ekaterina Doubrovina
Jingyi Xiang
Leonid Dubrovsky
Manuel Direito de Morais Guerreiro
Michael Curcio
Nicholas Veomett
Richard J O'Reilly
P2860
P2888
P304
P3181
P356
10.1038/NBT.3349
P407
P577
2015-09-21T00:00:00Z
P6179
1007772367